Announcements
A retrospective comparative study confirmed that both vaccines provide strong protection against symptomatic SARS-CoV-2 infection. Excerpt from the Press Release: CAMBRIDGE, Mass., Dec. 15, 2021 /PRNewswire/ — nference, the AI-driven health technology company, announced today publication of a peer-reviewed study in Med that analyzed Mayo Clinic based data with nference artificial intelligence (AI) software to…
Read More
Breast Cancer Index reaffirmed as a significant predictive and prognostic diagnostic tool to personalize extended endocrine decisions Excerpt from the Press Release: MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating that Breast Cancer Index™ (BCI) not only predicts preferential recurrence-prevention benefit from extended endocrine therapy (EET), but…
Read More
-88.6% of Evaluable 1L TNBC Patients Achieved Tumor Reduction- -Disease Control Rate of 92.8% and 81.4% of Evaluable Patients with PD-L1 Positive and PD-L1 Negative Tumors, Respectively- -Median PFS Improvement of 47% and 30% Compared to IMpassion130 Benchmark for Patients with PD-L1 Positive and PD-L1 Negative Tumors, Respectively- – Safety Consistent with Expectations for the Three…
Read More
Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in combination with an immunomodulatory drug in patients with multiple myeloma Preclinical data shared at TIGIT Therapies Digital Summit highlight evidence for multifaceted mechanism of…
Read More
Preclinical pseudovirus data and structural modeling shows ABP 310 retains activity and potency against the SARS-CoV-2 Omicron variant mutations ABP 310 EUA possible as early as 2022 Excerpt from the Press Release: WOBURN, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) — Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of…
Read More
New DESTINY-Breast03 data presented at SABCS 2021 showed AstraZeneca and Daiichi Sankyo’s ENHERTU demonstrated a similar benefit in patient subgroups, including in patients with stable brain metastases, versus T-DM1 Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–New results from the DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki)demonstrated a higher progression-free survival (PFS) and objective…
Read More
Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented Excerpt from the Press Release: PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for…
Read More
Excerpt from the Press Release: DUBLIN, Ireland and BOSTON, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today at the 2021 San Antonio Breast Cancer Symposium (SABCS), presented encouraging clinical data on samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, that support its…
Read More
Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancer Trial combines CAN-2409 with immune checkpoint inhibitor treatment after inadequate tumor response to initial checkpoint inhibitor therapy Collaboration may identify early markers of response and inform patient selection for treatment Excerpt from the Press…
Read More
In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progression-free survival for patients, with survival benefit observed across patient subgroups The safety profile of the combination was consistent with known risks of each treatment agent Following the positive topline at an interim analysis, a supplemental biologics license application in this indication is currently under…
Read More